Idelalisib Plus Anti-Cd20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL

Hematological Oncology - United Kingdom
doi 10.1002/hon.55_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer

Journal of Cancer
Oncology
2020English

Early Second‐line Therapy Is Associated With Improved Episodic Memory in Anti‐NMDA Receptor Encephalitis

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2019English

Idelalisib Bolsters CLL Regimen

Cancer Discovery
Oncology
2016English

Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

First-Line Ibrutinib Confirmed for CLL

Cancer Discovery
Oncology
2018English

Pediatric Response to Second-Line Antiretroviral Therapy in South Africa

PLoS ONE
Multidisciplinary
2012English

First-Line Therapy of CD20+ Diffuse Large B-Cell Lymphoma: Facts and Open Questions

Haematologica
Hematology
2009English

Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-Line Therapy for Patients With Autoimmune Hepatitis

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2017English

Switching Multiple Sclerosis Patients With Breakthrough Disease to Second-Line Therapy

PLoS ONE
Multidisciplinary
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy